Clonal Architecture of ASXL1-mutated Myelofibrosis
Status: Recruiting
Location: See all (13) locations...
Intervention Type: Biological
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
Prospective study to decipher the clonal architecture of ASXL1-mutated primary and secondary myelofibrosis and its impact on prognosis
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Adults (age ≥18 years),
• Affiliated to the national social security system,
• ASXL1 mutated primary or secondary myelofibrosis,
• Signed the consent to participate in the study,
• Included, or consenting to be included, in the national clinical-biological database of France Intergroupe Syndrome Myéloprolifératifs (FIM).
Locations
Other Locations
France
CHU Angers
RECRUITING
Angers
CHRU Brest
NOT_YET_RECRUITING
Brest
CH Cholet
NOT_YET_RECRUITING
Cholet
CHU Henri MONDOR
RECRUITING
Créteil
Institut Paoli Calmettes
RECRUITING
Marseille
CHU Nantes
NOT_YET_RECRUITING
Nantes
AP-HP Hôpital Saint Louis
NOT_YET_RECRUITING
Paris
Hôpital Bicêtre
RECRUITING
Paris
CHU de Bordeaux
RECRUITING
Pessac
CHU Lyon
RECRUITING
Pierre-bénite
CH de Cornouaille
NOT_YET_RECRUITING
Quimper
CHRU Tours - Hôpital Bretonneau
RECRUITING
Tours
CH de Vannes
NOT_YET_RECRUITING
Vannes
Contact Information
Primary
Margaux Wiber, PharmD.
margaux.wiber@chu-angers.fr
0033241355553
Time Frame
Start Date: 2023-04-24
Estimated Completion Date: 2031-04-23
Participants
Target number of participants: 50
Treatments
Experimental: CLONEMF cohort
Related Therapeutic Areas
Sponsors
Leads: University Hospital, Angers